Cantor Fitzgerald Analysts Give Shire (SHPG) a $222.00 Price Target
Several other equities research analysts also recently issued reports on SHPG. Zacks Investment Research upgraded shares of Shire from a sell rating to a hold rating in a research note on Tuesday, August 8th. Jefferies Group restated a hold rating and issued a $206.00 price objective (down previously from $216.00) on shares of Shire in a research note on Wednesday, August 9th. Barclays downgraded shares of Shire from an overweight rating to an equal weight rating in a research note on Friday, August 11th. Evercore ISI started coverage on shares of Shire in a research note on Wednesday, August 16th. They issued an outperform rating and a $196.00 price objective on the stock. Finally, ValuEngine downgraded shares of Shire from a buy rating to a hold rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. Shire currently has an average rating of Buy and an average target price of $212.18.
Shares of Shire (NASDAQ:SHPG) traded up $0.67 during mid-day trading on Tuesday, reaching $143.36. The company’s stock had a trading volume of 925,200 shares, compared to its average volume of 1,137,182. Shire has a one year low of $137.17 and a one year high of $192.15. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The firm has a market capitalization of $44,010.00, a P/E ratio of 9.81, a PEG ratio of 0.79 and a beta of 1.59.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion for the quarter. During the same quarter last year, the business earned $3.17 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. sell-side analysts expect that Shire will post 15 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Harding Loevner LP lifted its holdings in shares of Shire by 18,894.4% during the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after acquiring an additional 126,865,607 shares during the period. Maverick Capital Ltd. lifted its holdings in shares of Shire by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after acquiring an additional 322,610 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Shire by 35.3% during the third quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock valued at $266,613,000 after acquiring an additional 454,092 shares during the period. Glenview Capital Management LLC lifted its holdings in shares of Shire by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after acquiring an additional 707,500 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Shire by 6.4% in the third quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock valued at $245,997,000 after buying an additional 96,115 shares during the last quarter. 20.28% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-shire-shpg-a-222-00-price-target/1752220.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.